Lorenzo Cinci

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 4

Top Topics

Prostate Cancer

Anti Inflammatory

Dna Damage Response

Top Venues

BMC pulmonary medicine

Oxidative medicine and cellular longevity

Zeitschrift fur Naturforschung. C, Journal of biosciences

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Cosimo Nardi, Andrea Magnini, Linda Calistri, Edoardo Cavigli, Anna Julie Peired, Vieri Rastrelli, Edoardo Carlesi, Giulia Zantonelli, Olga Smorchkova, Lorenzo Cinci, Martina Orlandi, Nicholas Landini, Edoardo Berillo, Chiara Lorini, Jessica Mencarini, Maria Grazia Colao, Leonardo Gori, Valentina Luzzi, Chiara Lazzeri, Elisa Cipriani, Manuela Bonizzoli, Filippo Pieralli, Carlo Nozzoli, Alessandro Morettini, Federico Lavorini, Alessandro Bartoloni, Gian Maria Rossolini, Marco Matucci Cerinic, Sara Tomassetti, Stefano Colagrande
Doubts and concerns about COVID-19 uncertainties on imaging data, clinical score, and outcomes. BMC pulmonary medicine 23 (1) (2023)
Elisabetta Bigagli, Lorenzo Cinci, Mario D'Ambrosio, Patrizia Nardini, Francesca Portelli, Roberta Colucci, Maura Lodovici, Alessandro Mugelli, Cristina Luceri
Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study. Oxidative medicine and cellular longevity 2021 (2021)
Mario D'Ambrosio, Elisabetta Bigagli, Lorenzo Cinci, Antonella Gori, Cecilia Brunetti, Francesco Ferrini, Cristina Luceri
Ethyl acetate extract from Cistus x incanus L. leaves enriched in myricetin and quercetin derivatives, inhibits inflammatory mediators and activates Nrf2/HO-1 pathway in LPS-stimulated RAW 264.7 macrophages. Zeitschrift fur Naturforschung. C, Journal of biosciences 76 (1-2) (2020)
Elisabetta Bigagli, Cristina Luceri, Maria De Angioletti, Konstantin Chegaev, Mario D'Ambrosio, Chiara Riganti, Elena Gazzano, Simona Saponara, Mariangela Longini, Francesca Luceri, Lorenzo Cinci
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. Investigational new drugs 36 (6) (2018)